肝脏靶向腺相关病毒载体介导的基因治疗在犬血友病A模型中的长期随访
该研究对8只重度血友病A犬进行单次门静脉输注BDD-cFVIII AAV载体治疗,中位随访10.8年,6只应答犬持续表达FVIII:C(中位一期法12.7%,发色法7.2%),年化出血率从3.9次/年降至0.3次/年(P=.003),所有犬肝脏检出载体DNA,未发现慢性肝病或肝脏恶性肿瘤。
要点
- 中位随访10.8年,6只应答犬持续表达FVIII:C,年化出血率从3.9次/年降至0.3次/年(P=.003)。
- 所有犬肝脏检出AAV-BDD-cFVIII DNA(中位0.15 vg/二倍体基因组),仅肝脏检出BDD-cFVIII mRNA。
- 抗AAV衣壳中和抗体持续存在且随时间下降,但仍阻止同一衣壳再给药;尸检未发现慢性肝病或肝脏恶性肿瘤。
核心结论
- 载体递送后持续FVIII表达和出血表型改善超过十年,这是临床前模型中最长的随访报告,支持AAV介导基因治疗的长期疗效和安全性。
研究设计与样本
- 对8只重度血友病A犬(雄性4只半合子,雌性4只纯合子)进行单次门静脉输注B-domain-deleted(BDD)犬FVIII(cFVIII)AAV载体,中位剂量1.25×10^13 vg/kg,其中AAV2=4只、AAV6=3只、AAV8=1只,中位随访10.8年(8.2-12.0年)。
主要发现
- 6只应答犬持续表达FVIII:C,中位一期法12.7%,发色法7.2%。
- 年化出血率治疗前3.9次/年 vs 治疗后0.3次/年(P=.003)。
- 所有犬肝脏检出AAV-BDD-cFVIII DNA(中位0.15 vg/二倍体基因组),4只犬脾脏检出较低水平(中位0.005 vg/二倍体基因组)。
- 仅肝脏检出BDD-cFVIII mRNA,与肝特异性启动子一致。
- 尸检未发现慢性肝病或肝脏恶性肿瘤的证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Questions remain concerning the long-term efficacy, safety, and site(s) of transgene expression following adeno-associated vector (AAV) therapy. We report a long-term follow-up of 8 (male = 4, hemizygous, and female = 4, homozygous) dogs with severe hemophilia A treated with a single portal vein infusion of a B-domain-deleted (BDD)-canine FVIII (cFVIII) AAV vector (median dose = 1.25 × 1013 vg/kg, AAV2 = 4, AAV6 = 3, and AAV8 = 1). After a median follow-up of 10.8 years (8.2-12.0 years), persistent FVIII:C (median one-stage = 12.7%, chromogenic = 7.2%) was seen in all responding dogs (n = 6), with improvement in annualized bleed rates (pre = 3.9 vs post = 0.3 event per year; P = .003). Anti-AAV capsid neutralizing antibodies (nAbs) toward the dosed capsid were detected throughout the study, with limited cross-reactivity to other capsids. nAb titers for all capsid serotypes declined with time, although they remained at levels precluding redosing with the same capsid. AAV-BDD-cFVIII DNA was detected in the liver of all dogs (median = 0.15 vg per diploid genome), with lower levels in the spleen in 4 dogs (median = 0.005 vg per diploid genome). Consistent with the liver-specific promoter, BDD-cFVIII mRNA was only detected in the liver. Postmortem examination demonstrated no evidence of chronic liver disease or liver malignancy. Persistent FVIII expression and an improved bleeding phenotype was seen for more than a decade after vector delivery. This is the longest follow-up reported in a preclinical model supporting long-term efficacy and safety of AAV-mediated gene therapy.
引用
- Batty P, Mo AM, Hurlbut D, et al. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A. Blood. 2022. PMID: 35405003. doi:10.1182/blood.2021014735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。